Cooley LLP announced today that it is advising Jazz Pharmaceuticals in its pending acquisition of EUSA Pharma. The Cooley team was led by Mergers & Acquisitions partner Jennifer Fonner DiNucci, based in Palo Alto.

Consideration in the deal includes $650 million in cash, subject to certain adjustments, plus a potential $50 million milestone payment in cash based upon EUSA Pharma’s lead product, Erwinaze, achieving a specified U.S. net sales target in 2013.  EUSA is a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom.

In connection with the transaction announcement, Jazz Pharmaceuticals also announced that Barclays Bank PLC has provided it with a commitment letter for a $500 million term loan and a $100 million revolving credit facility.  Credit finance partner Gian-Michele a Marca, based in San Francisco, led the Cooley team on the financing aspects of the transaction.

The Cooley team advising on the acquisition included Palo Alto-based associatesDan Espinoza and Robin Bennett, Palo Alto-based partners Marya PostnerGlen Sato and Barbara Kosacz, Palo Alto-based associates Jennifer Raab and Tracy Huang Harrison, Palo Alto-based partner Mark Windfeld-Hansen, Colorado-based associate Aaron Pomeroy, Palo Alto-based partner Francis Fryscak, Washington, D.C.-based Megan Browdie, San Diego-based associates Amy WoodSoo Kim andMegan Arthur, San Diego-based special counsel Michelle Lara, Palo Alto-based special counsel Ann Polus, Palo Alto-based partner Gregory Tenhoff, Palo Alto-based special counsel Todd Bontemps, Palo Alto-based partner Chadwick Mills and Colorado-based partner Francis Wheeler.

The San Francisco-based Cooley team advising on the financing included associatesMichael Tollini and Jason Savich.


Related Posts:

Leave a Reply